A genus of ascomycete yeasts that includes both a proven therapeutic probiotic (S. boulardii) and species associated with disease states (S. cerevisiae enriched in CRC mycobiome). This dual nature -- commensal/probiotic versus disease-associated -- parallels the bacterial genus ruminococcus and highlights the importance of species-level resolution in mycobiome studies.
S. boulardii -- Therapeutic Probiotic
- The best-characterized fungal probiotic, with demonstrated efficacy in:
- C. difficile infection: reduces recurrence by 50-60% when combined with antibiotics; inhibits toxin A/B binding to colonocytes and degrades toxin receptor sites.
- Anti-inflammatory effects: secretes anti-inflammatory factors that inhibit NF-kB signaling and reduce IL-8 and TNF-alpha production in intestinal epithelial cells.
- Barrier protection: upregulates tight junction proteins and secretory IgA production.
- Antibiotic-associated diarrhea: reduces incidence by approximately 50% across meta-analyses.
- Unlike bacterial probiotics, S. boulardii is inherently resistant to all antibacterial antibiotics, making it uniquely suited for co-administration during antibiotic therapy.
- Produces proteases that degrade bacterial toxins, including C. difficile toxin A and cholera toxin.
S. cerevisiae in Disease
Colorectal Cancer Mycobiome
- S. cerevisiae is enriched in the CRC mycobiome in multiple cohorts. Saccharomycetaceae showed significant reductions in CRC in some studies, suggesting context-dependent effects [huang 2024 gut fungi ibd colorectal cancer].
- Interacts with bacterial communities: Saccharomyces abundance positively correlated with Bifidobacterium, Roseburia, and Ruminococcus in IBD patients [huang 2024 gut fungi ibd colorectal cancer].
Cardiometabolic Disease
- Saccharomyces enriched in HTN+CKD comorbidity patients; positively associated with IFN-gamma, IL-4, and eGFR [qiu 2023 gut mycobiome hypertension ckd].
- Present in hypertensive cohorts (8.46% of fungal community in HTN vs lower in normotensive controls) [wei 2025 gut mycobiome cardiometabolic disease].
- S. boulardii supplementation failed to improve cardiac function in the GutHeart trial for heart failure.
Crohn's Disease and ASCA
- Anti-Saccharomyces cerevisiae antibodies (ASCA) are a well-established serological marker for Crohn's disease, suggesting immune sensitization to this yeast in the inflamed gut.
- ASCA positivity distinguishes Crohn's from UC and is associated with more aggressive disease phenotype.
Metal Biosorption
- Saccharomyces species have significant metal biosorption capacity, binding heavy metals to cell wall components (mannoproteins, glucans, chitin).
- S. cerevisiae cell walls bind cadmium, lead, copper, zinc, and chromium from solution, a property exploited in industrial bioremediation.
- In the gut context, dietary or supplemental yeast may reduce bioavailable metal concentrations, potentially mitigating metal-induced dysbiosis.
- Zinc-dependent alcohol dehydrogenase and Cu/Zn-superoxide dismutase are key metalloenzymes in Saccharomyces biology.
Key Metabolites
- Ethanol -- primary fermentation product of S. cerevisiae; small amounts produced in the gut may affect hepatic metabolism.
- Beta-glucans -- cell wall polysaccharides that stimulate Dectin-1 immune receptor, upregulating tight junction proteins and modulating macrophage function [huang 2024 gut fungi ibd colorectal cancer].
- Proteases -- S. boulardii secretes serine proteases that degrade bacterial toxins and pro-inflammatory signaling molecules.
- Short-chain fatty acids -- indirect contribution via cross-kingdom metabolic interactions with SCFA-producing bacteria.
Connections
- clostridioides difficile -- S. boulardii is a proven therapeutic against CDI recurrence
- colorectal cancer -- S. cerevisiae enriched in CRC mycobiome; ASCA antibodies relevant
- crohns disease -- ASCA antibodies as serological marker; immune sensitization to yeast
- cardiovascular disease -- enriched in HTN+CKD; failed to improve heart failure in GutHeart trial
- cadmium -- cell wall biosorption capacity for Cd and other heavy metals
- lead -- metal biosorption may reduce bioavailable Pb in the gut
- zinc -- Zn-dependent enzymes; cell wall Zn-binding capacity
- copper -- Cu/Zn-SOD for oxidative stress defense
- dysbiosis -- S. boulardii counters dysbiosis; S. cerevisiae may signal disease states
- inflammation -- S. boulardii anti-inflammatory (NF-kB inhibition); beta-glucans immunomodulatory
- gut metal microbiome -- metal biosorption capacity links fungal biology to metal homeostasis
- roseburia -- positive correlation in IBD mycobiome-bacteriome interactions